Cargando…

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma

BACKGROUND: Preoperative radiotherapy (RT) is commonly used to treat localised soft-tissue sarcomas (STS). Hypoxia is an important determinant of radioresistance. Whether antiangiogenic therapy can ‘normalise' tumour vasculature, thereby improving oxygenation, remains unknown. METHODS: Two coho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewin, J, Khamly, K K, Young, R J, Mitchell, C, Hicks, R J, Toner, G C, Ngan, S Y K, Chander, S, Powell, G J, Herschtal, A, Te Marvelde, L, Desai, J, Choong, P F M, Stacker, S A, Achen, M G, Ferris, N, Fox, S, Slavin, J, Thomas, D M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264446/ https://www.ncbi.nlm.nih.gov/pubmed/25321190 http://dx.doi.org/10.1038/bjc.2014.537

Ejemplares similares

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor
por: Michael, M, et al.
Publicado: (2010)

Targeting lymphangiogenesis to prevent tumour metastasis
por: Achen, M G, et al.
Publicado: (2006)

The VEGF signaling pathway in cancer: the road ahead
por: Stacker, Steven A., et al.
Publicado: (2013)

Emerging Roles for VEGF-D in Human Disease
por: Stacker, Steven A., et al.
Publicado: (2018)

Control of Gene Expression by Exosome-Derived Non-Coding RNAs in Cancer Angiogenesis and Lymphangiogenesis
por: Arcucci, Valeria, et al.
Publicado: (2021)

Targeting lymphatic vessel functions through tyrosine kinases
por: Williams, Steven P, et al.
Publicado: (2010)

Elevated level of inhibin-α subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer
por: Balanathan, P, et al.
Publicado: (2009)

Systematic high-content genome-wide RNAi screens of endothelial cell migration and morphology
por: Williams, Steven P., et al.
Publicado: (2017)

A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC)
por: Ferris, Robert L, et al.
Publicado: (2015)

The connection between lymphangiogenic signalling and prostaglandin biology: A missing link in the metastatic pathway
por: Karnezis, Tara, et al.
Publicado: (2012)

Comparison of four 3D conformal treatment techniques to optimise radiotherapy treatment for anal cancer
por: Cray, Alison, et al.
Publicado: (2014)

Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma
por: Ursprung, Stephan, et al.
Publicado: (2021)

Pharmacodynamic analysis of tumour perfusion assessed by (15)O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies
por: Scott, Andrew M, et al.
Publicado: (2012)

Clinical applications of molecular imaging in sarcoma evaluation
por: Hicks, Rodney J, et al.
Publicado: (2005)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

Sunitinib induced nephrotic syndrome and thrombotic microangiopathy
por: Jha, P. K., et al.
Publicado: (2013)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
por: Mahalingam, D, et al.
Publicado: (2011)

Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D
por: McColl, Bradley K., et al.
Publicado: (2003)

A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer
por: Michael, M, et al.
Publicado: (2009)

Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma
por: Bharwani, N, et al.
Publicado: (2014)

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
por: Kong, G., et al.
Publicado: (2014)

The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment
por: Hendry, Shona A., et al.
Publicado: (2016)

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
por: Martin-Broto, Javier, et al.
Publicado: (2020)

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST
por: Hansson, E K, et al.
Publicado: (2013)

Intestinal-specific activatable Myb initiates colon tumorigenesis in mice
por: Malaterre, J, et al.
Publicado: (2016)

The use of RT-PCR for determination of separate end-points for the strains IB H120 and IB D274 in titration of the combination vaccine Poulvac IB(®) primer
por: Geerligs, H.J., et al.
Publicado: (2013)

Drug-induced immune thrombocytopenic purpura secondary to sunitinib
por: Trinkaus, M., et al.
Publicado: (2008)

Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer
por: Girling, Jane E, et al.
Publicado: (2010)

I.B.S. vacuum tests
por: Waddup, M G
Publicado: (1972)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

Combining radiotherapy with sunitinib: lessons (to be) learned
por: Kleibeuker, Esther A., et al.
Publicado: (2015)

Raman and fluorescence micro-spectroscopy applied for the monitoring of sunitinib-loaded porous silicon nanocontainers in cardiac cells
por: Tolstik, E., et al.
Publicado: (2022)

Sentinel node procedure in Ib cervical cancer: a preliminary series
por: Lantzsch, T, et al.
Publicado: (2001)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J J, et al.
Publicado: (2018)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J. J., et al.
Publicado: (2017)

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
por: Thompson Coon, J S, et al.
Publicado: (2009)

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2008)

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma
por: Pinato, David J., et al.
Publicado: (2021)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ti5qdof5k24522ftu3ri640a1o